Merck Still a “Buy” at UBS after New Osteoporosis Drug Proves Useful in Clinical Trial (MRK)

Comment

Shutterstock photo

Pharmaceuticals maker Merck & Co., Inc. ( MRK ) on Friday received some bullish commentary from analysts at UBS.

The firm maintained its "Buy" rating and $45 price target on MRK, suggesting just a 5% upside to the stock's Thursday closing price of $42.91. UBS noted that the company's new osteoporosis drug, dubbed Odanacatib, has shown promise in recently trials.

Merck shares, which have risen nearly 14% year-to-date, were mostly flat in premarket trading Friday.

The Bottom Line
Shares of Merck ( MRK ) have a 3.92% dividend yield, based on last night's closing stock price of $42.91. The stock has technical support in the $38-$39 price area. If the shares can firm up, we see overhead resistance around the $45-$47 price levels.

Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com



This article appears in: Investing , Stocks


More from Dividend.com







Dividend.com
Contributor:

Dividend.com

Dividends
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com